FTC, in unusual move, leads Sanofi to terminate a drug research deal

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘’unprecedented.”